Preliminary data showed a remarkable activity of T-DXd in a cohort of 78 patients with heavily pretreated HER2 positive colorectal cancer (n = 53 in cohort A; n = 7 in cohort B; and n = 18 in cohort C) [40]. This evidence concerns the gene ERBB2 and colorectal cancer.